HI
IMVT icon

Harbour Investments’s Immunovant IMVT Stock Holding History

Harbour Investments’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58K Buy
41
+31
+310% +$944 ﹤0.01% 4101
2026
Q1 		$248 Buy
+10
New +$259 ﹤0.01% 4407
2023
Q4 		– Sell
-43
Closed -$1.65K – 3156
2023
Q3 		$1.65K Buy
+43
New +$972 ﹤0.01% 2597

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Harbour Investments's IMVT Position: Q2 2026 in Review

Harbour Investments increased its Immunovant (IMVT) stake by 310% in Q2 2026, buying an estimated $944 and bringing the position to 41 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #4101.

Harbour Investments first reported a position in IMVT in Q3 2023 and has held it in 3 quarters since. The position peaked at $1.65K in Q3 2023. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Harbour Investments held 41 shares of Immunovant worth $1.58K as of Q2 2026.
  • Harbour Investments bought 31 Immunovant shares in Q2 2026, an estimated $944.
  • Immunovant made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4101 holding.
  • Harbour Investments first reported a position in Immunovant in Q3 2023 and has held it in 3 quarters since.
  • Harbour Investments's Immunovant position peaked at $1.65K in Q3 2023.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.